Latest Vitrafy Life Sciences (ASX:VFY) News

Wellnex led the healthcare market after agreeing to sell Pain Away for up to A$21.3 million. Neuren and Lumos also rose strongly as sales, royalties and product orders improved.

Vitrafy Life Sciences reported an 80% revenue surge and halved its net loss, buoyed by US military validation and major blood network partnerships. A $32 million capital raise fuels its US commercial expansion and manufacturing scale-up.

Xenitra led the healthcare board after a three-year Chinese pharmaceutical deal, while Artrya and InteliCare delivered the week’s biggest contrasting moves. Across the sector, companies raised cash, won regulatory support and pushed deeper into US hospitals and clinics.

Vitrafy Life Sciences reported a breakthrough 94.4% post-thaw platelet recovery in US Army Phase II testing, secured major US blood network partnerships, and raised $32 million to accelerate US expansion and device manufacturing.

Lumos led healthcare stocks higher after widening its US urgent care rollout, while Tissue Repair tumbled on its plan to leave the ASX. Strong trial updates, FDA steps and fresh funding kept the sector busy, even as several stocks fell despite good news.

Vitrafy Life Sciences has partnered with the historic Hoxworth Blood Center to deploy its next-generation cryopreservation technology, aiming to address a critical gap in red blood cell preservation ahead of legacy technology discontinuation in 2027.

Healthcare stocks split into two camps this week: names with fresh data or contracts found buyers, while capital raisings and trial shock sent others sharply lower. The biggest move came from Cynata’s return to trade, but steady progress in Alzheimer’s, oncology, diagnostics and aged care software also kept the sector busy.

Vitrafy Life Sciences has launched a non-underwritten Share Purchase Plan to raise approximately A$2 million, offering existing Australian and New Zealand shareholders the chance to buy shares at A$2.60 each, matching the recent institutional placement price.

A brutal sell-off in a few small caps sat alongside takeover bids, fresh capital raisings and strong gains in medtech. The week split the market in two: buyers chased clear funding and approval news, while weaker stories sank fast after reopening.

Healthcare shares were driven by regulation, capital and commercial deals this week. The biggest moves came from companies that either moved closer to US sales or raised cash to get there.

Vitrafy Life Sciences has secured A$30 million through an institutional placement to ramp up manufacturing of its Guardion cryopreservation devices and expand US sales operations, with an additional A$2 million sought via a shareholder plan.

A handful of extreme moves set the tone, from DXN’s explosive AI data centre rerating to steep sell-offs in small-cap explorers. Deals, funding and fresh drilling results drove the week, but several gap-ups lost steam as traders banked profits.